Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: A systematic review and meta-analysis

Transplantation

Volumn 94, Issue 10, 2012, Pages 1041-1048

  Cohen, Jordana B ^a   Gordon, Craig E ^a   Balk, Ethan M ^b   Francis, Jean M ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Calcimimetics; Cinacalcet; Hypercalcemia; Hyperparathyroidism; Kidney transplantation

Indexed keywords

CALCITRIOL; CALCIUM; CINACALCET; CREATININE; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ABDOMINAL DISCOMFORT; ACUTE GRAFT REJECTION; ADULT; ARTICLE; BK VIRUS INFECTION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HAND PARESTHESIA; HEART INFARCTION; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY INFECTION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UROSEPSIS; VOMITING;

CALCIMIMETIC AGENTS; CALCIUM; FEMALE; HUMANS; HYPERPARATHYROIDISM; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NAPHTHALENES; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84870246784     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31826c3968     Document Type: Article

References (65)

1. Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004; 19: 1281.
2. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13: 551.
3. Dumoulin G, Hory B, Nguyen NU, et al. No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997; 29: 746.
4. Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506.
5. Egbuna OI, Taylor JG, Bushinsky DA, et al. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007; 21: 558.
6. Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5: 1934.
7. Frick TW, Fryd DS, Sutherland DE, et al. Hypercalcemia associated with pancreatitis and hyperamylasemia in renal transplant recipients. Data from the Minnesota randomized trial of cyclosporine versus antilymphoblast azathioprine. Am J Surg 1987; 154: 487.
8. Mazzaferro S, Pasquali M, Taggi F, et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009; 4: 685.
9. Ambühl PM, Meier D, Wolf B, et al. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999; 34: 875.
10. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429.
11. Triponez F, Clark O, Vanrenthergem Y, et al. Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surgery 2008; 248: 18.
12. Lee PP, Schiffmann L, Offermann G, et al. Effects of parathyroidectomy on renal allograft survival. Kidney Blood Press Res 2004; 27: 191.
13. Evenepoel P, Claes K, Kuypers D, et al. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005; 20: 1714.
14. Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669.
15. Cueto-Manzano AM, Konel S, Freemont AJ, et al. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 2000; 35: 227.
16. Kruse AE, Eisenberger U, Frey FJ, et al. The caclimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 7: 1311.
17. Apostolou T, Kollia K, Damianou L, et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. Transplant Proc 2006; 38: 3514.
18. Leca N, Laftavi M, Gundroo A, et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6: 2391.
19. Srinivas TR, Schold JD, Womer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 323.
20. Szwarc I, Argiles A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82: 675.
21. Bergua C, Torregrosa JV, Cofan F, et al. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Pro 2007; 39: 2254.
22. El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83: 546.
23. Serra AL, Savoca R, Huber AR, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007; 22: 577.
24. Bergua C, Torregrosa JV, Fuster D, et al. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008; 86: 413.
25. Kamar N, Gennero I, Spataru L, et al. Pharmacodynamic effect of cinacalcet after kidney transplantation: once-versus twice-daily dose. Nephrol Dial Transplant 2008; 23: 3720.
26. Carrasco FR, Perez-Flores I, Calvo N, et al. Treatment of persistent hyperparathyroidism in renal transplant patients with cinacalcet improves control of blood pressure. Transplant Proc 2009; 41: 2385.
27. Gomez Marques G, Obrador Mulet A, Vilar Gimeno A, et al. Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation. Transplant Proc 2009; 41: 2139.
28. Lopez V, Toledo R, Sola E, et al. Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant Proc 2009; 41: 2394.
29. Moutzouris DA, Charitaki E, Tsouka G, et al. Cinacalcet's efficacy and safety in tertiary hyperparathyroidism in renal transplant recipients. ASN Renal Week 2009 Abstract.
30. Toro Prieto FJ, Bernal Blanco G, NavarroGarciaM, et al. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism. Transplant Proc 2009; 41: 2144.
31. Borchhardt KA, Diarra D, Sulzbacher I, et al. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol 2010; 31: 482.
32. Borstnar S, Erzen B, Gmeiner Stopar T, et al. Treatment of hyperparathyroidism with cinacalcet in kidney transplant recipients. Transplant Proc 2010; 42: 4078.
33. Copley JB, Germain M, Stern L, et al. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc 2010; 42: 2503.
34. Guerra R, Auyanet I, Fernandez E, et al. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: Analysis after a year with cinacalcet. J Nephrol 2011; 24: 78.
35. Pinho LRS, Ribeiro Santos MJC, Pestana Vasconcelos M. Cinacalcet in the treatment of persistent hyperparathyroidism after kidney transplantation. Clin Nephrol 2011; 75: 263.
36. Schwarz A, Merkel S, Leitolf H, et al. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism. Transplantation 2011; 91: 560.
37. Serra AL, Wuhrmann C, Wuthrich RP. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis 2008; 52: 1151.
38. Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006; 109: 339.
39. Zitt E, Woess E, Mayer G, et al. Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism. Transplantation 2011; 92: 883.
40. Peng LW, Logan JL, James SH, et al. Cinacalcet-associated graft dysfunction and nephrocalcinosis in a kidney transplant recipient. Am J Med 2007; 120: e7.
41. Seikrit C, Muhlfeld A, Groene HJ, et al. Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic. Nat Rev Nephrol 2011; 7: 237.
42. Evenepoel P, Claes K, Kuypers DR, et al. Parathyroidectomy after successful kidney transplantation: a single center study. Nephrol Dial Transplant 2007; 22: 1730.
43. Trizna W, Edwards RM. Relaxation of renal arterioles by parathyroid hormone and parathyroid hormone-related protein. Pharmacology 1991; 42: 91.
44. Massfelder T, Parekh N, Endlich K, et al. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized rat. Br J Pharmacol 1996; 118: 1995.
45. Jespersen B, Randlov A, Abrahamsen J, et al. Effects of PTH(1Y34) on blood pressure, renal function, and hormones in essential hypertension: The altered pattern of reactivity may counteract raised blood pressure. Am J Hypertens 1997; 10: 1356.
46. Geara AS, Castellano MR, Bassil C, et al. Effects of parathyroid hormone on immune function. Clin Dev Immunol 2010; 2010: 418695. Epub.
47. Shasha SM, Kristal B, Steinberg O, et al. Effect of parathyroidectomy on T cell function in patients with primary hyperparathyroidism. Am J Nephrol 1989; 9: 25.
48. Kotzmann H, Köller M, Abela C, et al. Effects of parathyroid hormone and serum calcium on the phenotype and function of mononuclear cells in patients with primary hyperparathyroidism. Eur J Clin Invest 1998; 28: 353.
49. Amanzadeh J, Reilly RF. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2006; 2: 136.
50. Riella LV, Rennke HG, Grafals M, et al. Hypophosphatemia in kidney transplant recipients: report of acute phosphate nephropathy as a complication of therapy. Am J Kidney Dis 2011; 57: 641.
51. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519.
52. Ohkido I, Segawa H, Yanagida R, et al. Cloning, gene structure and dietary regulation of the type-IIc Na/Pi cotransporter in the mouse kidney. Pflugers Arch 2003; 446: 106.
53. Kawarazaki H, Shibagaki Y, Fukumoto S, et al. Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study. Ther Apher Dial 2011; 5: 481.
54. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2004; 68: 1793.
55. Hryszko T, Brzosko S, Rydzewska-Rosolowska A, et al. Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. Int Urol Nephrol 2012; 44: 1479.
56. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584.
57. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study. Ann Intern Med 2008; 152: 640.
58. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1232.
59. El-Shafey EM, Alsahow AE, Alsaran K, et al. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial 2011; 15: 547.
60. Duntas LH, Stathatos N. Cinacalcet as alternative treatment for primary hyperparathyroidism: Achievements and prospects. Endocrine 2011; 39: 199.
61. Cho ME, Duan Z, Chamberlain CE, et al. Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. Transplant Proc 2010; 42: 3554.
62. National Institute for Health and Clinical Excellence. Hyperparathyroidism: Cinacalcet. http://www.nice.org.uk/TA117.
63. Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007; 49: 801.
64. Henschkowski J, Bischoff-Ferrari HA, Wüthrich RP, et al. Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation. Kidney Blood Press Res 2011; 34: 97.
65. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.